Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab, and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison by Fautrel, B et al.
ORIGINAL RESEARCH
Comparative effectiveness of improvement
in pain and physical function for baricitinib
versus adalimumab, tocilizumab and
tofacitinibmonotherapies in rheumatoid
arthritis patients who are naïve to treatment
with biologic or conventional synthetic
disease-modifying antirheumatic drugs:
a matching-adjusted indirect comparison
B Fautrel,1 B Zhu,2 P C Taylor,3 M van de Laar,4 P Emery,5 F De Leonardis,2
C L Kannowski,2 C Nicolay,2 Z Kadziola,2 I De La Torre,2 R Fleischmann6
ABSTRACT
Objective To compare improvement in pain and physical
function for patients treated with baricitinib, adalimumab,
tocilizumab and tofacitinib monotherapy from randomised,
methotrexate (MTX)-controlled trials in conventional
synthetic disease-modifying antirheumatic drugs
(csDMARDs)/biologic (bDMARD)-naïve RA patients using
matching-adjusted indirect comparisons (MAICs).
Methods Data were from Phase III trials on patients receiving
monotherapy baricitinib, tocilizumab, adalimumab, tofacitinib or
MTX. Pain was assessed using a visual analogue scale
(0–100 mm) and physical function using the Health Assessment
Questionnaire-Disability Index (HAQ-DI). An MAIC based on
treatment-arm matching, an MAIC with study-level matching and
Bucher’smethodwithoutmatching compared change in outcomes
between therapies. Matching variables included age, gender,
baseline disease activity and baseline value of outcome measure.
Results With all methods, greater improvements were observed
in pain and HAQ-DI at 6 months for baricitinib compared with
adalimumab and tocilizumab (p<0.05). Differences in treatment
effects (TEs) favouring baricitinib for pain VAS for treatment-arm
matching, study-levelmatchingandBucher’smethod, respectively,
were−12,−12and−12 for baricitinib versus adalimumaband−7,
−7 and −9 for baricitinib versus tocilizumab; the difference in TEs
for HAQ-DI was −0.28, −0.28 and −0.30 for adalimumab and
−0.23, −0.23 and −0.26 for tocilizumab. For baricitinib versus
tofacitinib, no statistically significant differences for pain
improvement were observed except with one of the threemethods
(Bucher method) and none for HAQ-DI.
Conclusions Results suggest greater pain reduction and
improved physical function for baricitinib monotherapy
compared with tocilizumab and adalimumab monotherapy. No
statistically significant differences in pain reduction and
improved physical function were observed between baricitinib
and tofacitinib with the MAIC analyses.
INTRODUCTION
Despite substantial improvements over the last
two decades in the management of patients
with rheumatoid arthritis (RA), the treat-to-
target approach has led rheumatologists to
focus on inflammatory disease activity, whereas
patients generally consider the reduction of
pain and fatigue and improvement of physical
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Key messages
What is already known about this subject?
► Large, randomised clinical trials have demonstrated
the efficacy of baricitinib, adalimumab, tocilizumab
and tofacitinib monotherapy in pain reduction and
HAQ-DI improvement compared with methotrexate
monotherapy, but there are no head-to-head trials
between these treatments in patients with RA who
are naïve to treatment with conventional synthetic or
biologic disease-modifying antirheumatic drugs.
What does this study add?
► The results from this study add evidence, through
indirect comparison, that suggest greater pain
reduction and improved physical function for
baricitinib monotherapy compared with tocilizumab
and adalimumab monotherapy.
How might this impact on clinical practice or
future developments?
► The findings from this study will help clinicians
evaluate different therapies to reduce pain and
improve physical function in the treatment of RA
patients.
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function to be more important.1–3 Their assessment, in
addition to healthcare provider (HCP)-reported disease
activity measures, should help physicians determine the
best treatment management for the patient. In the RA-
BEAM randomised controlled trial (RCT), with concomi-
tant methotrexate (MTX), baricitinib 4 mg one time
per day demonstrated greater improvements in pain and
physical function compared with adalimumab 40 mg every
other week in a population of patients who had had an
insufficient response to MTX.4 There is an absence, how-
ever, of prospective, head-to-head trials between different
biologic or targeted synthetic disease-modifying antirheu-
matic drugs (b/tsDMARDs) in MTX-naïve RA patients,
a population that could be considered more sensitive to
change in PROs because they had not yet experienced the
irreversible consequences of the longstanding disease.
In the absence of data from RCT, indirect comparison
methodologies, such as NetworkMeta-Analysis (NMA) and,
in more recent years, Matching-Adjusted Indirect Compar-
ison (MAIC), have been proposed to compare the efficacy
of different therapies based on aggregate data from differ-
ent RCTs, and they are commonly used for the purposes of
health technology appraisal.5–7 Compared with an NMA,
which is based on the assumption that treatment effects
(TEs) are only relative to a common comparator (eg, pla-
cebo) with no additional difference between the trials in the
distribution of effect-modifying variables,7 8 MAIC builds
upon the indirect comparison through additional adjust-
ment of effect-modifying variables.
An MAIC analysis uses patient-level data of a drug to
match with published data from comparators. Specifi-
cally, individual patient data from one or more studies
for one treatment are reweighted to match with the base-
line characteristics, which are known to be TE modifiers,
from a published study of another treatment. To have an
appropriate analysis, the study with patient-level data and
the study with published data must have a common refer-
ence arm for matching. After the matching with the indi-
vidual patient data, the weighted difference in mean
values of an outcome measure between the active arm
and the reference arm of one study is calculated and
compared with the difference from the other published
study.5
The objective of this analysis was to compare improve-
ment in pain and physical function between baricitinib,
adalimumab, tocilizumab and tofacitinib monotherapy
with an MAIC using data from randomised, MTX-
controlled trials in conventional synthetic DMARD
(csDMARD)/bDMARD-naïve RA patients.
METHODS
Study eligibility
The studies included in this analysis were derived from a prior
systematic literature review (SLR) that was designed for aNMA
conducted by Eli Lilly. The SLR synthesised the evidence of
treatments on measures of treatment response and effective-
ness, disease activity, physical function, radiographic outcomes,
safety andother keymeasures for adult patients withmoderate-
to-severeRAamong studies conducted from1999 to 2016. The
criteria for selection in the SLR and a flow chart describing the
screening for inclusion are in online supplementary figure 1.
For the purposes of the current analysis, we focused on the
population of patients with limited or no treatment with
csDMARDs in the SLR; 27 studies met this criterion. Of these
studies, 12 includedmonotherapyandanMTXtreatmentarm,
which constitutes the common comparator; and of these 12
studies, 5 reported on pain and physical function, asmeasured
by the Health Assessment Questionnaire-Disability Index
(HAQ-DI), at 6 months or 24±2 weeks, depending upon the
time points reported in the studies. These five studies were
included in the current analysis (table 1). The study designs
and inclusion and exclusion criteria for the studies have been
previously reported.6–11 Thedoses of themedications included
in theanalysiswereoral 4mgofbaricitinibdaily,9 subcutaneous
40 mg of adalimumab every other week,6 7 intravenous 8 mg/
kgof tocilizumabevery4weeks8 10 andoral 5mg tofacitinib two
times per day.11
Outcome measures
Pain was measured with the patient’s assessment of pain,
a visual analogue scale (VAS), ranging from 0 to 100 mm.
Physical function was measured with the HAQ-DI.12 13
The HAQ-DI consists of 24 questions referring to eight
domains: dressing/grooming, arising, eating, walking,
hygiene, reach, grip and activities. The score for the
HAQ-DI ranges from 0 to 3, with lower scores reflecting
better physical function and thus, less disability.
Matching-adjusted indirect comparisons (MAICs) and
sensitivity analyses
The primary MAIC in this analysis was based on the
Signorovitch method with weights applied to treat-
ment arms.5 14 Specifically, data from the baricitinib
4 mg treatment arm from the RA-BEGIN trial9 were
weighted to match the baseline characteristics that
are TE modifiers (age, gender, Disease Activity
Score-28 erythrocyte sedimentation rate [DAS28-
ESR], pain VAS and HAQ-DI) from the adalimumab
arm from PREMIER,6 7 tofacitinib 5 mg twice a day
arm from ORAL-START twice a day11 and tocilizu-
mab 8 mg/kg arm from FUNCTION.8 For reference,
the MTX monotherapy arms were also matched
between the trials. Analyses were conducted on
patients from RA-BEGIN who met the inclusion and
exclusion criteria of the respective comparator trials.
Sensitivity analyses were conducted with the inclusion
of disease duration as an additional matching vari-
able. Two other approaches, an MAIC based on the
Signorovitch method with study-level matching
(matching on the entire study, rather than by treat-
ment arm)5 and Bucher’s method without matching
adjustment,15 were also conducted as sensitivity ana-
lyses to determine the consistency of the findings.
Because of the prior experience patients in the
AMBITION study had with MTX, we also conducted
RMD Open
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Table 1 Study design and characteristics
Study
Study design and dosage
information Inclusion criteria Key exclusion criteria
Baricitinib (RA-
BEGIN,
NCT01711359)9
Patients were randomised 4:3:4 to
oral MTX one time per week (N=210),
baricitinib 4 mg (monotherapy) one
time per day (N=159), or the
combination of baricitinib+MTX
(N=215)
► Patients were ≥18 years
► Moderately-to-severely
active RA
► Patients had active disease
(TJC ≥6 and SJC ≥6)
► SerumCRP level ≥3.6mg/L
► Seropositive for RF or
ACPA
► No prior csDMARD therapy
and no prior bDMARD
► Recent clinically significant
infection and select laboratory
abnormalities
Tocilizumab
(AMBITION,
NCT00109408)10
Patients were randomised to
tocilizumab (TCZ) 8 mg/kg
intravenously every 4weeks (N=286),
or to MTX oral capsules, weekly
together with folate (>5 mg/week)
(N=284)
► Patients were ≥18 years
► ≥3 months of moderately-to
-severely active RA
► SJC of ≥6, TJC ≥8, CRP level
≥1.0mg/dLorESR≥28mm/h
at baseline
► Oral glucocorticoids and
NSAIDs were permitted if
stable >6 weeks
► Clinically unstable concurrent
illnesses
► Active or untreated latent TB
► Unsuccessful treatment with
TNFi
► Received MTX within 6 months
of randomisation or
discontinued MTX previously
Tocilizumab
(FUNCTION,
NCT01007435)8
Patients were randomised to 4 mg/
kg TCZ+MTX (N=288), 8 mg/kg TZC
+MTX (N=290), 8 mg/kg TCZ
+placebo (N=292) or placebo+MTX
(N=287); TCZ or placebo were
administered intravenously every 4
weeks
► Patients were ≥18 years
► ≤2 years of moderate-to-
severe RA
► SJC of ≥4, TJC of ≥6, CRP
level ≥1.0 mg/dL or ESR
≥28 mm/h at baseline
► Positive RF or ACPA or ≥1
erosion of hands, wrists or
feet attributable to RA
based on a central
radiographic reading
► Clinically unstable concurrent
illnesses and screened
according to local standards
► Active or untreated latent TB
► Had been unsuccessfully
treated with TNFi
► Had received MTX 6 months
prior to randomisation or had
discontinued MTX
Tofacitinib
(ORAL-START,
NCT01039688)11
Patients were randomised to
tofacitinib 5 mg two times per day
(BID, N=373) or tofacitinib 10 mg BID
(N=397) or MTX (N=186)
► Patients were ≥18 years
► ≥3 months of moderately-
to-severely active RA
► SJC of ≥6, TJC of ≥6, CRP
level >7.0 mg/L or ESR
>28 mm/h at baseline
► ≥3 distinct joint erosions on
radiographs, positive test
for IgM RF or ACPA
► Prior treatment with
lymphocyte-depleting or
alkylating agents
► Select lab abnormalities
► History of: another autoimmune
rheumatic disease except
Sjögren’s syndrome
► Serious infection
► Lymphoproliferative disorder
► Malignancy except adequately
treated non-metastatic basal/
squamous cell cancer of the skin
or cervical carcinoma in situ
► Evidence of active, latent or
inadequately treated
Mycobacterium TB infection
Adalimumab
PREMIER,
NCT00195663)6 7
Patients were randomised to
adalimumab 40 mg subcutaneously
every other week + weekly oral MTX
(N=268); adalimumab 40 mg
subcutaneously every other week
(adalimumab + placebo; N=274); or
weekly oral MTX (N=257)
► Patients were ≥18 years
► <3 years of RA
► SJC of ≥8, TJC of ≥10, CRP
level ≥1.5 mg/dL or ESR
≥28 mm/h at baseline
Patients who had received
treatment with MTX,
cyclophosphamide, cyclosporine,
azathioprine or >2 other DMARDs
ACPA, anti-citrullinated protein antibodies; bDMARD, biologic disease-modifying antirheumatic drugs; CRP, C reactive protein; ESR, erythro-
cyte sedimentation rate; IgM, immunoglobulin M; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; SJC, swollen joint count;
TB, tuberculosis; TCZ, tocilizumab; TJC, tender joint count; TNFi, tumour necrosis factor inhibitor.
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separate MAICs between baricitinib and tocilizumab,
one with data from AMBITION alone and the second
with data from AMBITION and FUNCTION
combined.8–10
Statistical analyses
Differences between weighted TE inmean change in pain
VAS and HAQ-DI from baseline to 6 months for bariciti-
nib and the reported TE for adalimumab, tocilizumab or
tofacitinib were compared. For adalimumab, mean
changes in pain and HAQ-DI were based on the mean
pain and HAQ-DI values reported at Week 26.7 The var-
iance of the weighted TE was estimated with the bootstrap
method with 1000 iterations.16 17 The differences and
their associated 95% CIs are presented and a p<0.05 was
considered statistically significant. Analyses were not
adjusted for multiplicity, and they were conducted with
SAS version 9.4 (Cary, NC) and R (version 3.3.3).
RESULTS
Baseline characteristics
Baseline characteristics are presented in table 2. For the
MTX arms across trials, the mean baseline pain VAS
ranged from 59 to 65 mm and the 6-month mean change
in pain ranged from −28.3 to −33.5 mm. Likewise, for the
MTX arm, themean baselineHAQ-DI values ranged from
1.5 to 1.7, and the 6-month mean change in HAQ-DI
ranged from −0.5 to −0.74 (table 3). The similarity of
the baseline pain and HAQ-DI scores and the similar
change in pain and HAQ-DI from the MTX control arm
across studies suggest comparability between the trials.
The baseline values of the variables used in matching
for all the trials are shown in table 4, which includes the
baseline variables for RA-BEGIN after the matching on
those variables. Because of the matching, the baseline
values for baricitinib are the same as those from the
published data for the respective comparator drugs. The
effective sample sizes from RA-BEGIN, with individual
patient-level data, are reduced as the consequence of
weighting and matching.
Pain
For the primary MAIC analysis, baricitinib-treated
patients showed greater improvement in pain at 6months
compared with adalimumab (treatment difference:
−12.3, 95% CI −17.9 to −6.6) and tocilizumab (treatment
difference: −7.3, 95% CI −14.2 to −0.38) (figure 1). Con-
sistent results were observed with the other indirect com-
parison methods. There were numerical, but no
statistically significant, differences in pain improvement
between baricitinib and tofacitinib with the primary ana-
lysis. With the sensitivity analyses, no statistically signifi-
cant differences were observed using the MAIC with
study-level matching; there were, however, significant dif-
ferences with Bucher method (treatment difference:
−7.1; −13.5 to −0.65). (figure 1)
Physical function
For the primaryMAIC analysis (figure 1), baricitinib-treated
patients were shown to have greater improvement in physi-
cal function at 6months compared with adalimumab (treat-
ment difference: −0.28, 95% CI −0.44 to −0.13) and
tocilizumab (treatment difference: −0.23, 95% CI −0.39 to
−0.07). Similar results were observed with the other indirect
comparisons. There were no differences between bariciti-
nib and tofacitinib with all methods (figure 1).
Sensitivity analyses
To confirm the robustness of these results, we con-
ducted sensitivity analyses in which disease duration
was an additional matching variable, and when data
from AMBITION and FUNCTION were analysed
together. These sensitivity analyses were generally con-
sistent with the direction and magnitude of the primary
results, except for the comparison with the AMBITION
data (figures 2a,b). The different patient characteristics
from AMBITION from those in the FUNCTION and RA-
BEGIN studies may have contributed to the differences,
as described in the discussion below.
DISCUSSION
The gold standard for assessing the relative effectiveness of
one medication compared with another is a properly pow-
ered head-to-head study using an appropriate metric as the
primary endpoint. There has not been a study conducted
comparing one JAK inhibitor with another, or with
a bDMARD, in MTX-naïve patients, as monotherapy. In
the absence of a head-to-head RCT, we applied an MAIC
to compare improvement in pain and physical function for
patients treated with baricitinib, adalimumab, tocilizumab
and tofacitinib monotherapy from randomised, MTX-
controlled trials in RA patients who were naïve to
csDMARDs and bDMARDs. TheMAIC enables greater flex-
ibility to adjust for patient characteristics and TE modifiers
and should provide a more robust indirect comparison
than other traditional indirect comparison methods, such
as a network meta-analysis.18 This MAIC analysis has been
used in the indirect comparison of efficacy in other rheu-
matic diseases, such as psoriatic arthritis.19 20 The results of
the current analysis suggest greater pain reduction with
improved physical function for baricitinib monotherapy
compared with tocilizumab and adalimumab monotherapy
with the primaryMAIC and sensitivity analyses. For compar-
isons between baricitinib and tofacitinib monotherapy,
greater pain reduction with baricitinib was not consistently
observed across the MAIC analyses, which did not allow for
a robust conclusion on a difference between the two mole-
cules. There were no differences observed between the two
JAK inhibitors for HAQ-DI. Similar observations were also
observed with models in which disease duration was an
additional matching variable and with models in which
the AMBITION and FUNCTION data were analysed
together.
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To our knowledge, this is the first systematic analysis that
compares patients receiving different csDMARD and
bDMARD monotherapies in MTX-naïve patients with RA.
This analytic approach offers many advantages over other
conventional pairwise meta-analyses.21 Of note, the inclu-
sion of active comparators provides more clinically relevant
information compared with meta-analyses with only pla-
cebo. We also included data from well-designed RCTs that
included large enough sample sizes to allow for more reli-
able estimations of differences between treatments.
There are, however, limitations intrinsic to the
MAIC approach and, for this reason, our results
should be interpreted with caution. The MAIC analy-
sis matches based on observed TE modifiers, but it is
not possible to control for variables that are unob-
served. Additionally, the application of the MAIC
reduces the effective sample size for the study with
patient-level data, RA-BEGIN in the current analysis,
which subsequently results in reduced power and
capability to detect differences between medications.
Importantly, the RCTs in the current analysis were
conducted at different time periods during which
more aggressive therapy was being introduced, with
different patients and investigators in different
regions of the world. These factors have the potential
to increase the variations in baseline characteristics
among the included studies, with consequent chal-
lenges in matching patients accurately. Of note, the
AMBITION trial included 33% of patients who had
been previously treated with MTX, but who had
stopped MTX >6 months. Patients from AMBITION
had a longer duration of disease, higher tender and
swollen joint counts and higher CRP levels than the
other studies included in this MAIC analysis; whereas,
patients from FUNCTION tended to show more simi-
lar characteristics to those in RA-BEGIN; the other
studies included patients who were naïve to treat-
ment. Because of this, we included the AMBITION
trial only as a sensitivity analysis. Also, parameters,
such as race and geographic location, were not
included in the analysis, because these parameters
were not widely reported in the original trial publica-
tions. Additionally, these variables and the inclusion
of geographic location have rarely been explored in
indirect comparisons. Lastly, the baricitinib RCT in
the MAIC was conducted before the drug and dosage
for baricitinib received regulatory approvals;
a monotherapy study with a 2 mg dose of baricitinib
was not conducted.
In conclusion, this MAIC suggests that among RA
patients who are naïve to csDMARDs and bDMARDs,
baricitinib 4 mg provides statistically significant
greater pain reduction and improvement of physical
function compared with adalimumab 40 mg and toci-
lizumab 8 mg/kg. No difference in pain reduction
was observed between baricitinib and two times
per day tofacitinib 5 mg with two of the three ana-
lyses employed, and no difference was observed in
improving physical function. Well-designed, properly
powered, head-to-head clinical trials are needed to
confirm whether there is a class effect for JAK inhi-
bitors over bDMARDs.
Figure 1 Treatment differences from indirect comparisons with matching by treatment arm (primary analysis), matching by study
and without matching. HAQ-DI, Health Assessment Questionnaire-Disability Index; MTX, methotrexate; VAS, visual analogue
scale.
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